• Home
  • COA Measures by Therapeutic Area
  • FAQ

You are about to leave this site.
The link you have selected will take you to a site outside of MSD. You will be redirected to another MSD Website.

MSD does not review or control the content of any non-MSD site. MSD does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-MSD site.
Redirection to:
CONTINUE

This site only provides information on MSD's clinical outcome assessment measures. It is not intended to provide any detail on medical products nor be a substitute for professional medical advice, diagnosis or treatment. MSD does not provide medical advice or medical services.

Do you want to learn more about COA measures?

  • Access our FAQ
    • Helpful Resources
      • FDA-NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and other Tools). Silver Spring (MD): Food and Drug Administration (US); 2016-. Glossary. 2016 Jan 28 [Updated 2021 Nov 29]
      • U.S. Food and Drug Administration. (2018, June 08). Patient-Focused Drug Development Glossary.
Top of page

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Last update: May 2022 - Terms of Use

 - Privacy Policy - Cookie Settings

This Web Accessibility icon serves as a link to download eSSENTIAL Accessibility assistive technology software for individuals with physical disabilities. It is being featured as part of a Disability Community Involvement initiative that reflects our commitment to Diversity, Inclusion,Corporate Citizenship and Social Responsibility.